Arcadia Biosciences, Inc., an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits. It also provides nutritional oils comprising gamma linolenic acid safflower oil to manufacturers of dietary and nutritional supplements, medical foods, dog food, and other products under the SONOVA brand; and arachidonic acid safflower oil that is used as an ingredient in infant nutrition products. In addition, the company has various programs under development comprising fiber resistant starch wheat, whole grain flour, and reduced gluten wheat programs. Arcadia Biosciences, Inc. has strategic collaborations with Dow AgroSciences and Ardent Mills LLC to develop and commercialize wheat varieties. The company was founded in 2002 and is headquartered in Davis, California.
Industry, Sector and Symbol
Industry Agricultural chemicals
Sub-IndustryN/A
SectorBasic Materials
Phone530-756-7077
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.46 million
Profitability
Miscellaneous
Employees42
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
Arcadia Biosciences (NASDAQ:RKDA) Frequently Asked Questions
What is Arcadia Biosciences' stock symbol?
Arcadia Biosciences trades on the NASDAQ under the ticker symbol "RKDA."
When did Arcadia Biosciences' stock split? How did Arcadia Biosciences' stock split work?
Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 23rd 2018. An investor that had 100 shares of Arcadia Biosciences stock prior to the reverse split would have 5 shares after the split.
How were Arcadia Biosciences' earnings last quarter?
Arcadia Biosciences Inc (NASDAQ:RKDA) announced its quarterly earnings data on Wednesday, March, 27th. The basic materials company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.62. The basic materials company had revenue of $0.44 million for the quarter, compared to the consensus estimate of $0.30 million. Arcadia Biosciences had a negative return on equity of 233.26% and a negative net margin of 920.77%. View Arcadia Biosciences' Earnings History.
When is Arcadia Biosciences' next earnings date?
What price target have analysts set for RKDA?
2 brokers have issued 12 month price objectives for Arcadia Biosciences' shares. Their forecasts range from $15.00 to $20.00. On average, they anticipate Arcadia Biosciences' stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 175.6% from the stock's current price. View Analyst Price Targets for Arcadia Biosciences.
What is the consensus analysts' recommendation for Arcadia Biosciences?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcadia Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcadia Biosciences.
What are Wall Street analysts saying about Arcadia Biosciences stock?
Here are some recent quotes from research analysts about Arcadia Biosciences stock:
- 1. National Securities analysts commented, "Breeding Tomorrow’s Crops. By utilizing gene editing technology to develop crops with enhanced nutritional profiles and growth characteristics, Arcadia Biosciences is a small cap investment that is addressing a large scale market opportunity.
Commercialization Around The Corner. A number of development initiatives are beginning to transition to commercialization, with two lead products expected to have initial revenues in the next 12 months. Several additional products are expected to convert from development to commercialization in the following 2 to 3 years, and we expect the company will move from a pre-commercial revenue business in 2018 to a $100 million revenue business in 2023.
Pivot Towards The Consumer. A strategic shift has taken shape in recent years, with trait development focused more on the consumer rather than the grower with crops like high fiber or low gluten wheat. This shift has enabled the development of several high revenue possibilities as food companies push to differentiate products with healthier ingredients and simpler labels that can stimulate organic growth and margin enhancement.
Capitalizing On Cannabis Legalization. On February 28th, RKDA announced that breeding efforts would expand into cannabis. While the sale of byproduct from field trials can bring in some modest near-term revenues, we believe the key to the value proposition is development of a portfolio of proprietary traits that could bring in high margin revenues or command a meaningful M&A premium over the long term." (4/17/2019)
- 2. HC Wainwright analysts commented, "Valuation methodology, risks and uncertainties. Our valuation utilizes a discounted cash flow-based approach that derives a $140M value for RS Wheat, using a 15% discount rate, 30% tax rate and 10% manufacturing spend." (2/28/2019)
- 3. According to Zacks Investment Research, "Arcadia Biosciences, Inc. is engaged in developing and commercializing agricultural products primarily in the United States. The Company's product includes nitrogen use crops, salt tolerant plants, sunflower oil and shelf-life produce. Arcadia Biosciences, Inc. is headquartered in Davis, California. " (2/14/2019)
Has Arcadia Biosciences been receiving favorable news coverage?
Media coverage about RKDA stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Arcadia Biosciences earned a news sentiment score of 1.5 on InfoTrie's scale. They also assigned news stories about the basic materials company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future.
Who are some of Arcadia Biosciences' key competitors?
What other stocks do shareholders of Arcadia Biosciences own?
Who are Arcadia Biosciences' key executives?
Arcadia Biosciences' management team includes the folowing people:
- Mr. Rajendra Ketkar, Pres, CEO & Director (Age 65)
- Mr. Matthew T. Plavan, CFO, Sec. & Pres of Arcadia Specialty Genomics (Age 55)
- Dr. Zhongjin Lu Ph.D., Director of Product Devel. (Age 53)
- Ms. Sarah Reiter, Chief Commercial Officer (Age 47)
When did Arcadia Biosciences IPO?
(RKDA) raised $66 million in an initial public offering on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO.
Who are Arcadia Biosciences' major shareholders?
Arcadia Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Virtu Financial LLC (0.29%). Company insiders that own Arcadia Biosciences stock include Eric J Rey and Zhongjin Lu. View Institutional Ownership Trends for Arcadia Biosciences.
Which major investors are selling Arcadia Biosciences stock?
How do I buy shares of Arcadia Biosciences?
Shares of RKDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcadia Biosciences' stock price today?
One share of RKDA stock can currently be purchased for approximately $6.35.
How big of a company is Arcadia Biosciences?
Arcadia Biosciences has a market capitalization of $30.33 million and generates $1.46 million in revenue each year. The basic materials company earns $-13,480,000.00 in net income (profit) each year or ($5.35) on an earnings per share basis. Arcadia Biosciences employs 42 workers across the globe.
What is Arcadia Biosciences' official website?
How can I contact Arcadia Biosciences?
Arcadia Biosciences' mailing address is 202 COUSTEAU PLACE SUITE 105, DAVIS CA, 85018. The basic materials company can be reached via phone at 530-756-7077 or via email at [email protected]
MarketBeat Community Rating for Arcadia Biosciences (NASDAQ RKDA)
MarketBeat's community ratings are surveys of what our community members think about Arcadia Biosciences and other stocks. Vote "Outperform" if you believe RKDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RKDA will underperform the S&P 500 over the long term. You may vote once every thirty days.
